Literature DB >> 1279851

Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1.

S Takaya1, Y Iwaki, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1279851      PMCID： PMC2965439          DOI： 10.1097/00007890-199211000-00031

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  14 in total

1.  Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone.

Authors:  M Moran; M F Mozes; M S Maddux; S Veremis; C Bartkus; B Ketel; R Pollak; C Wallemark; O Jonasson
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

Review 2.  Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

Authors:  T E Starzl; K Abu-Elmagd; A Tzakis; J J Fung; K A Porter; S Todo
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 3.  Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction.

Authors:  T E Starzl; M Ishikawa; C W Putnam; K A Porter; R Picache; B S Husberg; C G Halgrimson; G Schroter
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

4.  The nature of experimental second-set kidney transplant rejection. 2. The mimicking of the haemodynamic upset by pharmacological and other means.

Authors:  W J Dempster
Journal:  Br J Exp Pathol       Date:  1971-04

5.  Treatment of primary liver graft nonfunction with prostaglandin E1.

Authors:  P D Greig; G M Woolf; S B Sinclair; M Abecassis; S M Strasberg; B R Taylor; L M Blendis; R A Superina; M F Glynn; B Langer
Journal:  Transplantation       Date:  1989-09       Impact factor: 4.939

6.  Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response.

Authors:  L Makowka; C Miller; P Chapchap; L Podesta; C Pan; D Pressley; V Mazzaferro; C O Esquivel; S Todo; B Banner
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

7.  Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys.

Authors:  Thomas E Starzl; Anthony J Demetris; Satoru Todo; Yoogoo Kang; Andreas Tzakis; Rene Duquesnoy; Leonard Makowka; Barbara Banner; Waldo Concepcion; Kendrick A Porter
Journal:  Clin Transplant       Date:  1989       Impact factor: 2.863

8.  Hyperacute renal allograft rejection in the rabbit. Vasoconstriction demonstrated by microangiography.

Authors:  Y Terada; A Ueno
Journal:  Transplantation       Date:  1983-03       Impact factor: 4.939

9.  Prostaglandin as an effective antirejection therapy in rat renal allograft recipients.

Authors:  T B Strom; C B Carpenter
Journal:  Transplantation       Date:  1983-04       Impact factor: 4.939

10.  Prostaglandin E inhibits the production of human interleukin 2.

Authors:  R S Rappaport; G R Dodge
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307
View more
  25 in total

1.  Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts.

Authors:  S Takaya; A Jain; A Yagihashi; K Nakamura; M Kobayashi; K Takeuchi; S Suzuki; Y Iwaki; A J Demetris; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1999-08       Impact factor: 1.066

2.  Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.

Authors:  S Takaya; O Bronsther; K Abu-Elmagd; H Ramos; J J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1993-06       Impact factor: 1.066

3.  Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.

Authors:  K Abu-Elmagd; S Todo; J Fung; J Demetris; J Rakela; A S Rao; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1994

4.  Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch.

Authors:  H R Doyle; I R Marino; F Morelli; C Doria; L Aldrighetti; J McMichael; J Martell; T Gayowski; T E Starzl
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

5.  The Future of Xenotransplantation.

Authors:  Thomas E Starzl
Journal:  Ann Surg       Date:  1992-10-01       Impact factor: 12.969

6.  A cost analysis of alprostadil in liver transplantation.

Authors:  D G Smith; K S Henley; C S Remmert; S L Hass; I D McLaren
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

7.  Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted?

Authors:  H R Doyle; I R Marino; N Jabbour; G Zetti; J McMichael; S Mitchell; J Fung; T E Starzl
Journal:  Transplantation       Date:  1994-04-15       Impact factor: 4.939

8.  Baboon-to-human liver transplantation.

Authors:  T E Starzl; J Fung; A Tzakis; S Todo; A J Demetris; I R Marino; H Doyle; A Zeevi; V Warty; M Michaels
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

9.  Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies.

Authors:  S L Saidman; R J Duquesnoy; A J Demetris; J McCauley; H Ramos; G Mazariegos; R Shapiro; T E Starzl; J J Fung
Journal:  Transpl Immunol       Date:  1994       Impact factor: 1.708

10.  Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation.

Authors:  Nassim Kamar; Laurence Lavayssière; Fabrice Muscari; Janick Selves; Céline Guilbeau-Frugier; Isabelle Cardeau; Laure Esposito; Olivier Cointault; Marie Béatrice Nogier; Jean Marie Peron; Philippe Otal; Marylise Fort; Lionel Rostaing
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.